Sugi Predict

Sugi Predict / Compounds / SCHEMBL3158141

SCHEMBL3158141

SCHEMBL3158141

N#Cc1ccc(CN)cc1F

nearest known ligand 0.57

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 2/20 0.57
▸ LOXL2 Q9Y4K0 2/20 0.47
▸ DAO P14920 2/20 0.47
▸ NSD2 O96028 2/20 0.44
▸ CYP11B1 P15538 9/20 0.43
▸ CYP11B2 P19099 9/20 0.43
▸ MAOA P21397 1/20 0.41
▸ MAOB P27338 1/20 0.41
▸ KCNJ1 P48048 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6778748 0.98 TRPV4 (0.55) TRPV4LOXL2DAONSD2CYP11B1
Hydrochloric Acid SCHEMBL21798388 0.98 TRPV4 (0.55) TRPV4LOXL2DAONSD2CYP11B1
SCHEMBL6564705 0.86 TRPV4 (0.55) TRPV4DAOCYP11B1CYP11B2MAOA
SCHEMBL20168445 0.85 CYP11B2 (0.54) TRPV4LOXL2NSD2CYP11B1CYP11B2
SCHEMBL30751861 0.85 CYP11B2 (0.54) TRPV4LOXL2NSD2CYP11B1CYP11B2
Hydrochloric Acid SCHEMBL28803020 0.85 TRPV4 (0.53) TRPV4DAOCYP11B1CYP11B2MAOA
SCHEMBL51299 0.84 LOXL2 (0.47) TRPV4LOXL2NSD2MAOAMAOB
SCHEMBL31126027 0.84 LOXL2 (0.47) TRPV4LOXL2NSD2MAOAMAOB
SCHEMBL24872449 0.83 TRPV4 (0.61) TRPV4DAOCYP11B1CYP11B2MAOA
SCHEMBL6561624 0.83 TRPV4 (0.52) TRPV4DAONSD2CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2681215-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-04-22 — — EP claimed
US-20260124198-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS GILEAD SCIENCES INC (US) 2026-05-07 — — US disclosed
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-11 — — US disclosed
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-04 — — US disclosed
EP-4561993-A1 INHIBITORS OF PLASMA KALLIKREIN Rezolute, Inc. (US) 2025-06-04 — — EP disclosed
CN-120051460-A Plasma kallikrein inhibitors 瑞泽路特有限公司 2025-05-27 — — CN disclosed
US-20250129020-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-04-24 — — US disclosed
CN-119350433-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2025-01-24 — — CN disclosed
US-12195427-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2025-01-14 — — US disclosed
EP-4479388-A1 ANTIVIRAL NAPHTHYRIDINONE COMPOUNDS Gilead Sciences, Inc. (US) 2024-12-25 — — EP disclosed
US-20050137168-A1 Heterocyclyl substituted 1-alkoxy acetic acid amides HOFFMANN-LA ROCHE INC. 2005-06-23 — — US disclosed
EP-1513807-A1 PHARMACEUTICAL COMBINATION AstraZeneca AB (SE) 2005-03-16 — — EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 — — US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 — — WO disclosed
CN-1487919-A Novel mandelic acid derivatives and their use as thrombin inhibitors — 2004-04-07 — — CN disclosed
US-20040019033-A1 Mandelic acid derivatives and their use as throbin inhibitors ASTRAZENECA AB (SE) 2004-01-29 — — US disclosed
WO-2003101956-A1 PHARMACEUTICAL COMBINATION ASTRAZENECA AB (SE) 2003-12-11 — — WO disclosed
EP-1347955-A1 NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS AstraZeneca AB (SE) 2003-10-01 — — EP disclosed
WO-2003028729-A2 PRODRUGS OF SUBSTITUTED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2003-04-10 — — WO disclosed
WO-2002044145-A1 NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS ASTRAZENECA AB (SE) 2002-06-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124198-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS ZC3HAV1, CCR1, CCR6 TRPV4 3162/4885LOXL2 2059/4885DAO 1055/4885
US-20040019033-A1 Mandelic acid derivatives and their use as throbin inhibitors ADAMTS1, ADAMTS13, ADAMTS7 TRPV4 3575/4885LOXL2 3176/4885DAO 169/4885
US-20050137168-A1 Heterocyclyl substituted 1-alkoxy acetic acid amides F12, TFPI, F11 TRPV4 3054/4885LOXL2 2676/4885DAO 144/4885
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 TRPV4 3055/4885LOXL2 3491/4885DAO 335/4885
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 TRPV4 4811/4885LOXL2 1380/4885DAO 2981/4885
US-12195427-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 TRPV4 4811/4885LOXL2 1380/4885DAO 2981/4885
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 TRPV4 4804/4885LOXL2 1473/4885DAO 2932/4885
US-20250129020-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 TRPV4 4811/4885LOXL2 1380/4885DAO 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.